Pluri (NASDAQ: PLUR) sells shares and warrants in $2.5M private deal

Rhea-AI Filing Summary

Pluri Inc. entered into a securities purchase agreement for a private placement of 625,000 common shares and warrants to purchase up to 625,000 common shares, at a combined price of $4.00 per share and warrant, expected to generate approximately $2.5 million in gross proceeds.

The investor is Chutzpah Holdings LP, a limited partnership beneficially owned by existing shareholder and director Alexandre Weinstein. The warrants are immediately exercisable at $4.25 per share for eighteen months and include a 35% beneficial ownership limitation. Pluri plans to use the funds for working capital and general corporate purposes, with closing expected around the end of April 2026, subject to customary conditions. The securities are being issued in an unregistered offering relying on exemptions under Section 4(a)(2) and/or Regulation S and cannot be sold in the United States without registration or a valid exemption.

Insights

Capital markets and dilution analyst

Pluri raises about $2.5M via a director-led private placement with warrants.

Pluri Inc. arranged a private financing with an existing director-linked entity for 625,000 common shares plus 625,000 warrants at a $4.00 unit price, targeting gross proceeds of about $2.5 million. The warrants are immediately exercisable at $4.25 for eighteen months.

The investor’s 35% beneficial ownership limitation caps how much of the company can be held via these securities, which can help manage concentration and potential control concerns. Because the deal is unregistered and uses Securities Act exemptions, resale in the U.S. will be constrained until registration or another exemption applies.

Use of proceeds is limited to working capital and general corporate purposes, a broad category that typically covers operating expenses and general business needs. Actual impact on existing shareholders will depend on the company’s overall capital structure and any future warrant exercises, which are not detailed here.

8-K Event Classification

3 items: 1.01, 3.02, 9.01

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 3.02 Unregistered Sales of Equity Securities Securities

The company sold equity securities in a private placement or other unregistered transaction.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001158780 0001158780 2026-03-25 2026-03-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): March 27, 2026 (March 25, 2026)

PLURI INC.

(Exact Name of Registrant as Specified in Its Charter)

Nevada		001-31392		98-0351734
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

MATAM Advanced Technology Park
Building No. 5
Haifa, Israel		3508409
(Address of Principal Executive Offices)		(Zip Code)

011 972 74 710 7171

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, par value $0.00001 per share		PLUR		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On March 25, 2026, Pluri Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”), effective as of March 24, 2026, with Chutzpah Holdings LP (the “Purchaser”), a limited partnership beneficially owned by Mr. Alexandre Weinstein, a non-U.S. investor and an existing shareholder and director of the Company (“Mr. Weinstein”), relating to a private placement offering (the “Offering”) of: (i) 625,000 common shares, par value $0.00001 per share (the “Common Shares”) of the Company, and (ii) warrants (the “Common Warrants”) to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and Common Warrant is $4.00. The Common Warrants will be exercisable immediately at an exercise price of $4.25 per share and will be exercisable until the expiration of the eighteen-month anniversary following closing of the Offering. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The Securities Purchase Agreement contains customary representations, warranties and indemnification obligations of the parties.

The gross proceeds to the Company from the Offering are expected to be approximately $2.5 million. The Company intends to use the proceeds from the Offering for working capital and general corporate purposes. The entirety of the Offering is expected to close on or about the end of April 2026, subject to the satisfaction of customary closing conditions.

The securities issued with respect to the Offering are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) of the Securities Act and/or Rule 903 of Regulation S promulgated thereunder. The securities have not been registered under the Securities Act and may not be sold in the United States absent registration or an exemption from registration.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The foregoing descriptions of the Securities Purchase Agreement and the Common Warrants are qualified in their entirety by reference to the full text of the Securities Purchase Agreement and the form of Common Warrants, copies of which are filed as Exhibits 10.1 and 4.1, respectively.

Item 3.02 Unregistered Sales of Equity Securities.

The response to this item is included in Item 1.01, Entry into a Material Definitive Agreement, and is incorporated herein in its entirety.

1

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
4.1		Form of Warrant
10.1		Securities Purchase Agreement
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Safe Harbor Statement

This Current Report on Form 8-K contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, the Company is using forward-looking statements when it discusses the expected closing of the Offering, the receipt of the proceeds from the Offering and the intended use of the proceeds from the Offering. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about the Company: the conditions to the closing of the Offering may not be met; changes in technology and market requirements; the Company may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; the Company’s products may not be approved by regulatory agencies; the Company’s technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; the Company may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with the Company’s processes; the Company’s products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; the Company’s patents may not be sufficient; the Company’s products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; and loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PLURI INC.
Date: March 27, 2026	By:	/s/ Liat Zalts
	Name:	Liat Zalts
	Title:	Chief Financial Officer

3

FAQ

What financing did Pluri Inc. (PLUR) announce in this 8-K?

Pluri Inc. announced a private placement offering of 625,000 common shares and warrants to purchase up to 625,000 additional shares. The combined purchase price is $4.00 per share and warrant, with expected gross proceeds of approximately $2.5 million before expenses.

Who is investing in Pluri Inc.’s new private placement and what is their relationship?

The investor is Chutzpah Holdings LP, a limited partnership beneficially owned by Alexandre Weinstein. Weinstein is described as a non-U.S. investor and an existing shareholder and director of Pluri Inc., meaning the financing comes from a party already connected to the company.

What are the key terms of the warrants issued in Pluri Inc.’s private placement?

The private placement includes warrants to purchase up to 625,000 common shares. These warrants are immediately exercisable at an exercise price of $4.25 per share, remain exercisable for eighteen months after closing, and include customary anti-dilution provisions plus a 35% beneficial ownership limitation.

How will Pluri Inc. use the approximately $2.5 million raised in this offering?

Pluri Inc. states that it intends to use the expected gross proceeds of approximately $2.5 million for working capital and general corporate purposes. This typically means funding ongoing operations, corporate expenses, and other general business needs rather than a specific earmarked project.

When is Pluri Inc.’s private placement expected to close?

The company expects the entire private placement to close on or about the end of April 2026, subject to satisfaction of customary closing conditions. These conditions typically include finalizing documentation and meeting standard legal and regulatory requirements for such transactions.

Are the securities issued in Pluri Inc.’s private placement registered with the SEC?

No, the securities issued in this transaction have not been registered under the Securities Act of 1933. They rely on exemptions under Section 4(a)(2) and/or Regulation S, and cannot be sold in the United States without registration or a valid exemption from registration.

Filing Exhibits & Attachments

5 documents

Agreements & Contracts

• EX-10.1 SECURITIES PURCHASE AGREEMENT 253.3 KB

Other Documents

• EX-4.1 FORM OF WARRANT 85.1 KB
• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB